Premium
In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene‐Based Prodrug Nanoparticles
Author(s) -
Cayre Fanny,
Mura Simona,
Andreiuk Bohdan,
Sobot Dunja,
Gouazou Sandrine,
Desmaële Didier,
Klymchenko Andrey S.,
Couvreur Patrick
Publication year - 2018
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700830
Subject(s) - squalene , förster resonance energy transfer , prodrug , in vivo , chemistry , cyanine , biophysics , combinatorial chemistry , nanotechnology , biochemistry , materials science , biology , fluorescence , physics , microbiology and biotechnology , quantum mechanics
Förster resonance energy transfer (FRET) is used here for the first time to monitor the in vivo fate of nanoparticles made of the squalene‐gemcitabine prodrug and two novel derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient FRET pair in the NIR region. Following intravenous administration, nanoparticles initially accumulate in the liver, then they show loss of their integrity within 2 h and clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key prerequisite before introduction into clinical settings.